News ArchivesRead News

Stem cell transplant boosts function slightly in Parkinson's monkeys

Tuesday December 04, 2012

Eryn Brown

Los Angeles Times - In a small but hopeful step for researchers working on therapies to treat Parkinson’s disease, a team in Japan has used stem cells harvested from bone marrow to restore function in monkeys with the debilitating condition.

The cell transplants didn’t cure the macaques, but did improve motor skills in the animals and appeared to do so safely, the scientists wrote Monday in the Journal of Clinical Investigation — suggesting that stem cells from bone marrow might someday be a useful source for treatments of Parkinson’s in humans.

“To the best of our knowledge, this study is the first to show restoration of dopaminergic function and motor behaviors in parkinsonian primate animals” after treatment with stem cell-derived neurons, they wrote.

Stem cells are early-stage precursor cells that develop into the mature cells in the body. Scientists have long hoped to learn how to use them to replace cells and tissues damaged by accident or disease.

Parkinson’s has seemed like a good candidate for stem cell-derived therapies because people with the disorder have lost cells in the brain, or neurons, that produce the neurotransmitter dopamine. (For more about Parkinson’s read this page from the NIH’s National Institute of Neurological Disorders and Stroke.) If stem cells could be coaxed to develop into healthy, functioning dopaminergic neurons and then introduced into the brain, the thinking goes, perhaps patients could get relief from tremors, loss of balance and other debilitating Parkinson’s symptoms.

The Japanese team, led by Takuya Hayashi of the RIKEN Center for Molecular Imaging Science in Kobe, Japan, conducted its research on a group of 10 adult macaque monkeys. They induced Parkinson’s disease on the left side of the animals’ bodies.

They removed bone marrow from the hip bonesof the macaques, isolating so-called mesenchymal stem cells — the same type of cells that are sometimes harvested to treat patients with leukemia. (While mesenchymal stem cells can differentiate to become a variety of different types of cells including bone, cartilage and fat, they are not the same as embryonic stem cells or induced pluripotent stem cells, which can develop into any type of cell in the body.) The team used a previously reported method to turn the mesenchymal stem cells into dopamine-producing neurons.

Hayashi and his colleagues studied the neurons they created in the lab to assure that they were indeed dopamine-producing, and then administered treated cells to five of the monkeys. Each of the five monkeys received cells derived from his own bone marrow. The remaining monkeys received sham treatments.

Animals who received the cell treatments had improved motor function, the team reported. What’s more, through the use of PET scans and postmortem tissue analysis, the researchers determined that the implanted neurons continued producing small amounts of dopamine for at least nine months. The monkeys did not develop tumors, always a concern with stem-cell based therapies. Because the cells came from the monkeys’ own bone marrow, tissue rejection wasn’t an issue either. And the stem cells' origin in mature animals — not fetuses — sidestepped availability issues and ethical considerations involved in using fetal tissue, the scientists wrote.

Before the treatment might be considered appropriate for humans, they said, further studies will be needed to improve the viability of the cells once implanted, and to boost their therapeutic effect. But, they added, the approach “may expand the availability of cell sources for cell-based therapies for patients with Parkinson’s disease.”

Recent News

Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show